Treatment of Hypokalemia in Hospital Setting
Intravenous potassium chloride supplementation is the preferred treatment for hypokalemia in the hospital setting, with dosing based on severity of potassium deficiency and clinical presentation. 1
Assessment and Classification
Hypokalemia is defined as serum potassium levels below 3.5 mEq/L and can be classified as 1, 2:
- Mild: 3.0-3.5 mEq/L
- Moderate: 2.5-2.9 mEq/L
- Severe: <2.5 mEq/L
Severe hypokalemia (≤2.5 mEq/L) requires urgent treatment as it can lead to muscle necrosis, paralysis, cardiac arrhythmias, and impaired respiration 3
Treatment Algorithm
Urgent Treatment Indications
- Serum potassium ≤2.5 mEq/L 2
- Presence of ECG changes (U waves, T-wave flattening, ST-segment depression) 4
- Neuromuscular symptoms (weakness, paralysis) 2
- Cardiac arrhythmias 4
- Patients on digitalis 5
Route of Administration
Intravenous (IV) Administration:
Oral Administration:
Dosing Guidelines
IV Potassium Chloride:
Oral Potassium Chloride:
Special Considerations
Patients on Kidney Replacement Therapy (KRT)
- Use dialysis solutions containing potassium to prevent hypokalemia during KRT 4
- Dialysate/replacement solutions with potassium concentration of 4 mEq/L can minimize hypokalemia in continuous KRT 4
Metabolic Acidosis
- For hypokalemia with metabolic acidosis, use alkalinizing potassium salts instead of potassium chloride 5:
- Potassium bicarbonate
- Potassium citrate
- Potassium acetate
- Potassium gluconate
Monitoring
- Check serum potassium levels 4-6 hours after IV replacement 1
- For oral replacement, check levels within 24 hours 1
- Monitor ECG in patients with severe hypokalemia or cardiac conditions 4
- Target potassium level of at least 4.0 mEq/L in patients with heart failure 4
Magnesium Correction
- Check magnesium levels as hypokalemia is often associated with hypomagnesemia 4
- Correct magnesium deficiency to facilitate potassium correction 6
Pitfalls and Caveats
- Small decreases in serum potassium may represent significant decreases in intracellular potassium, requiring substantial supplementation 3
- Avoid bolus administration of potassium for cardiac arrest suspected to be secondary to hypokalemia as it is ill-advised (Class III, LOE C) 4
- Controlled-release oral potassium preparations should be reserved for patients who cannot tolerate liquid or effervescent preparations due to risk of gastrointestinal ulceration and bleeding 5
- Monitor for rebound hyperkalemia, especially in patients with transcellular shifts 1
- Consider potential drug interactions, particularly with RAAS inhibitors and NSAIDs, which may affect potassium levels 5